Wow_老虎社区_美港股上老虎

go_gym_yo
2021-03-15

Wow

The Better Stock for 2021: Moderna or Novavax?

The wisdom of crowds may give us the answer.

The Better Stock for 2021: Moderna or Novavax?

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":322110557,"tweetId":"322110557","gmtCreate":1615782038579,"gmtModify":1703492865363,"author":{"id":3576407274098185,"idStr":"3576407274098185","authorId":3576407274098185,"authorIdStr":"3576407274098185","name":"go_gym_yo","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Wow</p></body></html>","htmlText":"<html><head></head><body><p>Wow</p></body></html>","text":"Wow","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/322110557","repostId":2119963079,"repostType":4,"repost":{"id":"2119963079","kind":"news","pubTimestamp":1615775939,"share":"https://www.laohu8.com/m/news/2119963079?lang=&edition=full","pubTime":"2021-03-15 10:38","market":"us","language":"en","title":"The Better Stock for 2021: Moderna or Novavax?","url":"https://stock-news.laohu8.com/highlight/detail?id=2119963079","media":"Motley Fool","summary":"The wisdom of crowds may give us the answer.","content":"<p>So, we want to find out what the smartest investors are saying about a stock. What's <a href=\"https://laohu8.com/S/AONE\">one</a> of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. It's a stock-picking game that uses the wisdom of crowds to find great investments.</p>\n<p>Here's how it works. Players predict which stocks will beat or lag the <b>S&amp;P 500</b> over a particular time frame. CAPS then gives players ratings based on their performance versus other players. And CAPS rates stocks according to the number of players who say they'll outperform. A key point: The game weighs the opinions of highly rated players more heavily.</p>\n<p>Motley Fool CAPS is fun, but more importantly, it can help you use the wisdom of crowds as you build or expand your portfolio. Let's give it a try with <b>Moderna</b> (NASDAQ:MRNA) and <b>Novavax</b> (NASDAQ:NVAX).</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e2ec578cbf9dca9211feed282d44bc44\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Moderna</h2>\n<p><b>CAPS rating:</b> 3 out of 5 stars</p>\n<p><b>What investors might be noticing:</b> They probably like the fact that Moderna has started generating revenue from its coronavirus vaccine. And the company expects $18.4 billion in product sales this year, according to advance purchase agreements so far. What's holding this stock back from a higher rating? Moderna shares climbed more than 400% last year; some might worry that the good news is priced in. Another concern is the vaccine's performance against new variants. Moderna says its vaccine can handle the new strains, but those tests were in vitro, not in living subjects.</p>\n<h2>Novavax</h2>\n<p><b>CAPS rating:</b> 2 out of 5 stars</p>\n<p><b>What investors might be noticing:</b> Novavax has reported strong data from a phase 3 trial of its coronavirus vaccine candidate and has built an extensive manufacturing network. The biotech also has another close-to-market candidate: a potential flu vaccine. What's holding Novavax back from a better score? The stock already surged more than 2,700% last year; some worry further gains may be limited. Another concern is competition. Three other coronavirus vaccines have already entered the U.S. market. It may be difficult for Novavax to carve out a share.</p>\n<h2>The Foolish bottom line</h2>\n<p>Of the 100 highest-rated stocks on CAPS, only <a href=\"https://laohu8.com/S/AONE.U\">one</a> has posted a negative performance over the past year. And of the six CAPS stocks that have surged more than 1,000% over the past year, four have three stars and two have five stars. So, the highest-rated stocks generally outperform over time. If we use CAPS wisdom, it looks like Moderna may be the better stock for 2021.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Better Stock for 2021: Moderna or Novavax?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Better Stock for 2021: Moderna or Novavax?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-15 10:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>So, we want to find out what the smartest investors are saying about a stock. What's one of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2119963079","content_text":"So, we want to find out what the smartest investors are saying about a stock. What's one of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. It's a stock-picking game that uses the wisdom of crowds to find great investments.\nHere's how it works. Players predict which stocks will beat or lag the S&P 500 over a particular time frame. CAPS then gives players ratings based on their performance versus other players. And CAPS rates stocks according to the number of players who say they'll outperform. A key point: The game weighs the opinions of highly rated players more heavily.\nMotley Fool CAPS is fun, but more importantly, it can help you use the wisdom of crowds as you build or expand your portfolio. Let's give it a try with Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX).\nImage source: Getty Images.\nModerna\nCAPS rating: 3 out of 5 stars\nWhat investors might be noticing: They probably like the fact that Moderna has started generating revenue from its coronavirus vaccine. And the company expects $18.4 billion in product sales this year, according to advance purchase agreements so far. What's holding this stock back from a higher rating? Moderna shares climbed more than 400% last year; some might worry that the good news is priced in. Another concern is the vaccine's performance against new variants. Moderna says its vaccine can handle the new strains, but those tests were in vitro, not in living subjects.\nNovavax\nCAPS rating: 2 out of 5 stars\nWhat investors might be noticing: Novavax has reported strong data from a phase 3 trial of its coronavirus vaccine candidate and has built an extensive manufacturing network. The biotech also has another close-to-market candidate: a potential flu vaccine. What's holding Novavax back from a better score? The stock already surged more than 2,700% last year; some worry further gains may be limited. Another concern is competition. Three other coronavirus vaccines have already entered the U.S. market. It may be difficult for Novavax to carve out a share.\nThe Foolish bottom line\nOf the 100 highest-rated stocks on CAPS, only one has posted a negative performance over the past year. And of the six CAPS stocks that have surged more than 1,000% over the past year, four have three stars and two have five stars. So, the highest-rated stocks generally outperform over time. If we use CAPS wisdom, it looks like Moderna may be the better stock for 2021.","news_type":1},"isVote":1,"tweetType":1,"viewCount":330,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":3,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}